Every UK clinician and pharmacist uses some combination of the emc, BNF, and NICE CKS. Most default to whichever one they learned with during training without consciously choosing between them. Understanding what each resource actually is — who creates it, what data it draws from, what question it is designed to answer — transforms ad hoc reference use into deliberate clinical decision-making. These three resources are not interchangeable. They are complementary — and knowing which to reach for in which situation is a core clinical skill.
The Comparison Table
| Feature | emc (SmPC) | BNF | NICE CKS |
|---|---|---|---|
| Owner | Datapharm (hosts); content owned by marketing authorisation holders | BMJ + Pharmaceutical Press (RCPCH/NPPG for BNFC) | NICE |
| Data source | Manufacturer submissions approved by MHRA | SmPCs + independent expert clinical input | NICE guidelines + systematic reviews + expert consensus |
| Editorial independence | None — manufacturer's approved document | Independently curated by BNF editorial committee | Independently authored by NICE clinical knowledge team |
| Update cycle | Updated when manufacturer submits a variation to MHRA (continuous) | Continuously updated online; print editions twice yearly | Continuously updated; individual topic review cycles vary |
| Intended audience | Healthcare professionals (regulatory reference) | Healthcare professionals (clinical prescribing) | Primary care clinicians (clinical management) |
| Legal status | Part of the marketing authorisation — prescribing outside it = off-label | Independent clinical formulary — NICE-accredited editorial process | Clinical management guidance — not a drug reference |
| Organisation | Product-led (one SmPC per product/strength/formulation) | Drug-led (one monograph per active substance across formulations) | Condition-led (one topic per clinical presentation) |
| Strengths | Comprehensive, regulatory authority, full adverse event data, excipient detail, complete interaction lists, pregnancy/lactation data | Clinically curated, practical UK prescribing doses, comparative drug class info, concise, interaction checker | Primary care management pathways, condition-led navigation, stepwise treatment guidance, referral criteria |
| Weaknesses | Verbose, no clinical context, no comparative information, readability issues, manufacturer-authored | Less comprehensive adverse event data than SmPC, may differ from SmPC on doses without explaining why | Not a drug reference, limited to conditions covered, primary care scope only |
| Access | Free (medicines.org.uk) | Free online (bnf.nice.org.uk); free app for UK healthcare professionals | Free (cks.nice.org.uk) |
| API availability | Datapharm API (commercial licensing) | Limited programmatic access | Limited programmatic access |
emc / SmPC: The Manufacturer's Regulatory Document
The emc (electronic Medicines Compendium) hosts the MHRA-approved Summary of Product Characteristics for every licensed medicine in the UK. The content is written by the marketing authorisation holder (the manufacturer) and approved by the MHRA as part of the marketing authorisation process. It is comprehensive — every licensed indication, every reported adverse event by frequency, every drug interaction identified in clinical trials and post-marketing surveillance, every excipient, every dose adjustment studied in every population. It is also unfiltered — no editorial voice separates the clinically important interaction from the pharmacokinetically trivial one.
The emc hosts over 14,000 documents — SmPCs, PILs, and Risk Minimisation Materials. It is updated continuously as manufacturers submit variations to the MHRA, meaning the emc version is always more current than any printed reference.
Reach for the emc/SmPC when: You need the manufacturer's complete data on a specific product. Specific scenarios: checking whether a specific formulation contains a problematic excipient (section 6.1 — lactose, azo dyes, peanut oil), finding the full list of reported adverse events with frequency data (section 4.8), verifying the exact licensed indications for a specific product (section 4.1 — is this on-label or off-label?), checking pregnancy/lactation safety data from the regulatory source (section 4.6), finding specific dose adjustments for renal impairment with exact GFR/creatinine clearance thresholds (section 4.2), and checking the complete drug interaction profile including evidence basis (section 4.5).
Do not reach for it when: You need a quick prescribing reference during a time-pressured consultation (the SmPC is too verbose for point-of-care use), you want comparative information across drugs in the same class (SmPCs cover one product at a time — they cannot compare ramipril with lisinopril), or you want management pathway guidance for a clinical condition (SmPCs are product-led, not condition-led — they tell you about the drug, not about the disease).
BNF: The Independent Clinical Formulary
The BNF is independently curated by a joint editorial committee of the British Medical Association and the Royal Pharmaceutical Society, published by BMJ and Pharmaceutical Press. The BNFC (for children) additionally involves RCPCH and NPPG editorial input. The BNF is NICE-accredited — meaning its editorial process meets NICE's published standards for evidence-based clinical guidance.
The BNF ingests SmPC data as its primary source material — but it does substantially more than republish SmPCs. The editorial committee adds clinical context (when to use a drug relative to alternatives), practical prescribing doses that reflect UK clinical consensus (which sometimes differ from the SmPC's licensed dose — the BNF dose for a drug may exceed or differ from the SmPC dose based on accumulated clinical evidence and expert agreement), comparative notes across drugs in the same therapeutic class (something no SmPC can provide), and guidance on monitoring, dose titration, switching, and interactions presented with clinical significance weighting.
The BNF monograph for ramipril, for example, covers all formulations of ramipril in a single entry — tablets, capsules, and oral solutions — whereas the emc has separate SmPCs for each branded formulation and strength. The BNF provides one unified clinical reference; the emc provides product-specific regulatory detail.
Reach for the BNF when: You are prescribing and need the standard UK dose. You want a quick overview of a drug class. You need to check an interaction at the point of care (the BNF interaction checker provides clinical significance ratings — the SmPC section 4.5 does not). You want to compare two drugs in the same class. You need concise, practically useful prescribing information during a time-pressured consultation. You need prescribing guidance for children (BNFC provides paediatric-specific dosing that many SmPCs lack entirely).
Do not reach for it when: You need the manufacturer's complete adverse event listing (the BNF curates the most clinically important events — it does not reproduce the full frequency-classified table from section 4.8). You need excipient information for a specific formulation (not in the BNF — go to the SmPC). You need to determine whether a specific use is licensed or off-label (the BNF sometimes lists uses accepted in UK clinical practice without explicitly distinguishing them from SmPC-licensed indications).
NICE CKS: The Primary Care Management Resource
NICE Clinical Knowledge Summaries are condition-led — organised by clinical presentation (hypertension, asthma, depression, urinary tract infection, acne, gout) rather than by drug. Each CKS topic provides a stepwise management pathway: when to investigate, what investigations to order, when to treat, what to prescribe first-line, when to step up, when to refer, what follow-up is needed. CKS is not a drug reference — it is a clinical management resource that includes drug recommendations within its management pathways but does not attempt to be a comprehensive formulary.
CKS topics are authored by the NICE clinical knowledge team, based on systematic review of NICE guidelines, Cochrane evidence, and expert clinical consensus. They are designed specifically for primary care clinicians managing conditions in general practice — not for hospital specialists, not for pharmacists verifying prescriptions, and not for regulatory purposes.
Reach for CKS when: You are seeing a patient in primary care and need the current evidence-based management pathway for their condition. You want to know first-line treatment, step-up criteria, investigation thresholds, referral criteria, safety-net advice, and follow-up intervals. CKS provides the "what to do" framework that neither the SmPC nor the BNF directly offers — it answers "how should I manage this patient's hypertension?" rather than "what are the properties of ramipril?"
Do not reach for it when: You need detailed drug information (dose adjustments, interactions, adverse events — use BNF or SmPC). You are managing a condition outside CKS's scope (specialist or hospital conditions may not have CKS topics). You need prescribing information for a specific drug rather than a management pathway for a condition.
The Decision Framework: Worked Scenarios
"Is this drug safe in pregnancy?" → SmPC section 4.6 (manufacturer's regulatory data) + BNF (clinical interpretation with any additional guidance) + UKTIS (UK Teratology Information Service — the specialist resource providing more detailed risk quantification than either SmPC or BNF, particularly useful for shared decision-making with patients).
"What's the standard UK dose for this patient?" → BNF first (reflects UK clinical consensus). Cross-reference SmPC section 4.2 if you need granular dose adjustment for renal or hepatic impairment (SmPC often provides more specific thresholds than BNF).
"What are ALL the reported adverse events for this drug?" → SmPC section 4.8 (complete manufacturer listing organised by system organ class and frequency). The BNF lists the clinically important adverse events; the SmPC lists everything reported.
"What's first-line treatment for this condition?" → NICE CKS (condition-led management pathway providing evidence-based treatment stepladder). Then cross-reference BNF for specific drug dosing within the CKS recommendation.
"Does this drug interact with the patient's other medications?" → BNF interaction checker (fastest for point-of-care queries — provides clinical significance ratings). SmPC section 4.5 (most comprehensive for detailed review — useful when the BNF flags an interaction and you need the full data to assess clinical significance in your specific patient).
"Does this specific formulation contain lactose?" → SmPC section 6.1 (excipient list) or section 2 (excipients with known effect). This information is not available in the BNF.
"How should I manage a patient who isn't responding to first-line treatment?" → NICE CKS (stepwise management — step-up criteria and second-line options). The BNF may list the drugs; CKS tells you when and how to escalate.
Other Resources Worth Knowing
MedicinesComplete. Premium database published by Pharmaceutical Press. Includes the BNF, BNFC, Stockley's Drug Interactions, Martindale: The Complete Drug Reference, and other specialist references. Institutional access is common in hospital pharmacy departments. The combined access is particularly useful for complex drug information queries where multiple sources need cross-referencing.
Stockley's Drug Interactions. The gold standard for detailed drug interaction information — more comprehensive and clinically contextualised than either the BNF interaction checker or SmPC section 4.5. Each interaction monograph provides the evidence basis, clinical significance assessment, mechanism, and management recommendation. Available via MedicinesComplete or as a standalone resource. Essential for complex polypharmacy queries.
Martindale: The Complete Drug Reference. The most comprehensive drug reference available — covers drugs used worldwide, including those not licensed in the UK. Useful for queries about drugs not in the BNF or for international formulations.
Dm+d (Dictionary of Medicines and Devices). The NHS's underlying technical dictionary of medicines and devices. Most clinicians never directly interact with it, but dm+d is the plumbing layer that powers EPS (Electronic Prescription Service), FP10 prescription printing, and every EHR's drug picker. When you select a drug in EMIS or SystmOne, the system is querying dm+d. Understanding that dm+d exists helps explain why some drug formulations appear in the clinical system and others do not — it is the technical infrastructure connecting prescribing to dispensing.
UKTIS (UK Teratology Information Service). Specialist service providing evidence-based information on drug safety in pregnancy. More detailed and nuanced than SmPC section 4.6 or BNF pregnancy advice. Provides quantified risk estimates rather than blanket "not recommended" statements. Available via toxbase.org or by direct consultation for complex cases.
Where iatroX Sits
Ask iatroX is not a replacement for any of these resources. It is a synthesis layer that queries across clinical guidelines (NICE, CKS), formulary data (BNF), and published evidence to provide guideline-grounded answers to clinical questions. When you ask iatroX a clinical question, the response synthesises across these sources and provides citations — rather than requiring you to navigate each resource separately and reconcile their outputs manually.
The primary resources remain authoritative for their specific purposes. The emc/SmPC for regulatory product information. The BNF for independent prescribing guidance. NICE CKS for condition-led management pathways. iatroX provides faster access to the synthesis across them — particularly useful during consultations where navigating three separate resources is impractical.